Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Recommendations of the Advisory Committee on Immunization Practices (ACIP)

Documenti analoghi

• Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Children Aged 6–18 Years with Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
  di: Bennett, Nancy M., et al.
  Pubblicazione: (2013)
• Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices
  di: Matanock, Almea, et al.
  Pubblicazione: (2019)
• Pneumococcal Vaccination Among Medicare Beneficiaries Occurring After the Advisory Committee on Immunization Practices Recommendation for Routine Use Of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults Aged ≥65 Years
  di: Black, Carla L., et al.
  Pubblicazione: (2017)
• 596 Potential public health impact of 13-valent pneumococcal conjugate vaccine use among US adults 65 years of age or older
  di: Pilishvili, Tamara, et al.
  Pubblicazione: (2014)
• Incremental Cost-Effectiveness of 13-valent Pneumococcal Conjugate Vaccine for Adults Age 50 Years and Older in the United States
  di: Stoecker, Charles, et al.
  Pubblicazione: (2016)